HOWL
Werewolf Therapeutics, Inc.1.0800
+0.0500+4.85%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
52.42MP/E (TTM)
-Basic EPS (TTM)
-1.62Dividend Yield
0%Recent Filings
8-K
Explores strategic alternatives
Werewolf Therapeutics reported Q4 2025 net loss of $8.4 million, down from $20.4 million a year earlier, with cash at $57.1 million funding operations into Q4 2026. The company hired Piper Sandler to explore strategic alternatives like sales or mergers to boost shareholder value. No timeline set. Process may fail.
10-K
FY2025 results
Werewolf Therapeutics posted FY2025 results ending December 31, 2025, as a clinical-stage biotech with no revenue disclosed in the 10-K. Quarterly breakdowns and profitability metrics remain undisclosed, leaving annual trends unclear. Cash position stood at market value implying modest liquidity as of June 30, 2025. No capex, buybacks, dividends, or debt details provided. No guidance offered for 2026. Clinical trial delays could stall quarterly momentum.
8-K
Strategic review launched
Werewolf Therapeutics launched a strategic review on February 24, 2026, hiring Piper Sandler as exclusive advisor to weigh options like sale, merger, asset sales, or partnerships. The move targets maximizing value from its INDUKINE/INDUCER platforms and clinical candidates WTX-124, WTX-330. No timeline set. No transaction assured.
8-K
64% workforce cut, $4.1M charge
Werewolf Therapeutics slashed 64% of its workforce on February 9, 2026, to cut operating expenses, with completion by February 13 and a $4.1 million one-time severance charge in Q1 2026. CFO Timothy Trost and CMO Randi Isaacs resigned effective that date, shifting to consulting roles at $250/hour; VP Finance Michael Urban steps in as principal financial officer. Cuts preserve cash amid strategic partnership pursuits for WTX-124 and WTX-330. Actual costs may vary.
8-K
Nasdaq bid price deficiency notice
Werewolf Therapeutics received a Nasdaq notice on February 4, 2026, for its common stock closing below $1.00 per share for 30 consecutive business days, violating the minimum bid rule. It has 180 days until August 3, 2026, to sustain $1.00 closes for 10 straight business days. No immediate delisting. Compliance isn't assured.
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
CTMX
CytomX Therapeutics, Inc.
4.25+0.12
HCWB
HCW Biologics Inc.
1.78-0.09
IMUC
EOM Pharmaceutical Holdings Inc
0.18+0.00
INBX
Inhibrx Biosciences, Inc.
81.57+5.36
JANX
Janux Therapeutics, Inc.
14.65-0.47
NWBO
Northwest Biotherapeutics, Inc.
0.25+0.01
TIL
Instil Bio, Inc.
11.25+0.13
WHWK
Whitehawk Therapeutics, Inc.
2.40+0.04
XLO
Xilio Therapeutics, Inc.
0.65+0.00